Integration of pharmacokinetic and pharmacodynamic indices of orbifloxacin in beagle dogs after a single intravenous and intramuscular administration

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 7, 2009, Pages 3024-3029

  Gebru, Elias ^a   Lee, Joong Su ^a   Chang, Zhi Qiang ^a   Hwang, Mi Hyun ^a   Cheng, Henrique ^b   Park, Seung Chun ^a  

^a Kyungpook National University   (South Korea)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORBIFLOXACIN; UNCLASSIFIED DRUG; VICTAS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; ESCHERICHIA COLI; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INTERMEDIUS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; CIPROFLOXACIN; DOGS; ESCHERICHIA COLI; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; PROTEUS MIRABILIS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 67649997354     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01346-08     Document Type: Article

References (27)

1. Aliabadi, F. S., B. H. Ali, M. F. Landoni, and P. Lees. 2003. Pharmacokinetics and PK/PD modeling of danofloxacin in camel serum and tissue cage fluids. Vet. J. 165:104-118.
2. Aliabadi, F. S., and P. Lees. 2002. Pharmacokinetics and pharmacokinetic/ pharmacodynamic integration of marbofloxacin in calf serum, exudate and transudate. J. Vet. Pharmacol. Ther. 25:161-174.
3. Boothe, D. M., A. Boeckh, R. B. Simpson, and K. Dubose. 2006. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy of 5 fluoroquinolones toward pathogens of dogs and cats. J. Vet. Intern. Med. 20:1297-1306.
4. Burgess, D. S. 1999. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 115:19S-23S.
5. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved guideline M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Davis, J. L., M. G. Papich, and A. Weingarten. 2006. The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J. Vet. Pharmacol. Ther. 29:191-197.
7. Elias, G., J.-S. Lee, M.-H. Hwang, Y.-S. Park, K.-H. Cho, Y.-H. Kim, and S.-C. Park. 2009. Pharmacokinetics and pharmacokinetic/pharmacodynamic integration of orbifloxacin in Korean Hanwoo cattle. J. Vet. Pharmacol. Ther. 32:219-228.
8. Fujii, T., S. Takatsu, M. Stegemann, M. Ogata, and S. I. Kamata. 2007. Clinical efficacy and safety of an injectable formulation of cefovecin in the treatment of bacterial skin infections of dogs. Jpn. J. Vet. Dermatol. 13:81-88.
9. Ganière, J. P., C. Mèdaille, and F. Etorè. 2004. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res. Vet. Sci. 77:67-71.
10. Goudah, A., and K. Abo-El-Sooud. 2008. Pharmacokinetics and milk penetration of orbifloxacin after intravenous and intramuscular injections to dromedary lactating camels (Camelus dromedaries). J. Vet. Pharmacol. Ther. 31:276-280.
11. Goudah, A., H. J. Cho, H. C. Shin, J. H. Shim, N. L. Regmi, M. Shimoda, and A. M. Abd El-Aty. 2008. Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. J. Vet. Pharmacol. Ther. doi:10.1111/j.1365-2885. 2008.01046.x.
12. Haines, G. R., M. P. Brown, R. R. Gronwall, K. A. Merritt, and L. K. Baltzley. 2001. Pharmacokinetics of orbifloxacin and its concentration in body fluids and in endometrial tissues of mares. Can. J. Vet. Res. 65:181-187.
13. Haritova, A. M., N. V. Rusenova, P. R. Paranov, L. D. Lashev, and J. Fink-Gremmels. 2006. Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys. Vet. Res. Commun. 30:775-789.
14. Heinen, E. 2002. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J. Vet. Pharmacol. Ther. 25:1-5.
15. Iherke, P. J., M. G. Papich, and T. C. Demanuelle. 1999. The use of fluoroquinolones in veterinary dermatology. Vet. Dermatol. 10:193-204.
16. Kay-Mugford, P. A., A. J. Weingarten, M. Ngoh, R. Zolynas, A. White, T. Katz, R. Simmons, and K. J. Varma. 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet. Ther. 3:402-408.
17. Marin, P., E. Escudero, E. Fernandez-Varon, and C. M. Carceles. 2007. Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. J. Dairy. Sci. 90:4219-4225.
18. Marin, P., E. Fernandez-Varon, E. Escudero, and C. M. Carceles. 2008. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. J. Vet. Pharmacol. Ther. 31:77-82.
19. Matsumoto, S., M. Nakai, M. Yoshida, and H. Katae. 1998. Absorption, distribution and excretion of orbifloxacin in swine and calves. J. Jpn. Vet. Med. Assoc. 51:13-18. (In Japanese with English abstract.)
20. Matsumoto, S., M. Takahashi, N. Kitadai, and H. Katae. 1998. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin. J. Vet. Med. Sci. 60:1259-1261.
21. Mckellar, Q. A., S. F Sanchez Bruni, and D. G. Jones. 2004. Pharmacokinetic/ pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J. Vet. Pharmacol. Ther. 27:503-514.
22. McKinnon, P. S., and S. L. Davis. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur. J. Clin. Microbiol. Infect. Dis. 23:271-288.
23. Mueller, M., A. de la Pena, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377.
24. Papich, M. G., and J. E. Riviere. 2001. Fluoroquinolone antimicrobial drugs, p. 898-917. In H. R. Adams (ed.), Veterinary pharmacology and therapeutics, 8th ed. Iowa State University Press, Ames.
25. Scott, D. W., J. Peters, and W. H. Miller, Jr. 2006. Efficacy of orbifloxacin tablets for the treatment of superficial and deep pyoderma due to Staphylococcus intermedius infection in dogs. Can. Vet. J. 47:999-1002.
26. Toutain, P. L., J. R. E. Del Castillo, and A. Bousquet- Mélou. 2002. The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res. Vet. Sci. 73:105-114.
27. Toutain, P. L., A. Bousquet-Mélou, and M. Martinez. 2007. AUC/MIC: a PK/PD index for antibiotics with time dimension or simply a dimensionless scoring factor. J. Antimicrob. Chemother. 60:1185-1188.